{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T07:40:06Z","timestamp":1756798806412,"version":"3.44.0"},"reference-count":26,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Berzosertib is a small\u2010molecule ataxia telangiectasia and Rad3\u2010related protein inhibitor. To assess the clearance mechanism(s) of berzosertib, a Phase 1, 2\u2010period, open\u2010label study was conducted in adults with advanced solid tumors who were treated with a single intravenous dose of 210\u00a0mg\/m<jats:sup>2<\/jats:sup> berzosertib containing approximately 3\u00a0\u00b5Ci of [<jats:sup>14<\/jats:sup>C]berzosertib (Period 1 Mass Balance), followed by assessment of berzosertib in combination with topotecan (Period 2 [Extension]) (NCT05246111). A total of 6 patients were enrolled in Period 1; 5 of them rolled over to Period 2. By Day 14, the mean total recovery of drug\u2010related material (total radioactivity) in urine and feces combined was 89.5% (feces: 73.7%; urine: 15.8%). Pharmacokinetic data suggested that a substantial amount of various circulating metabolites of berzosertib were present in plasma (78% of drug\u2010related material), with a longer terminal elimination half\u2010life of total radioactivity than unchanged berzosertib. M11, which is pharmacologically inactive, was identified as the major circulating metabolite (28.2% of drug\u2010related material). The safety profile of berzosertib and topotecan was consistent with prior clinical experience. Overall, the study established the predominant role of metabolic clearance in berzosertib disposition and characterized its metabolites structurally. No new safety concerns were identified with berzosertib as a single agent or in combination with topotecan.<\/jats:p>","DOI":"10.1002\/cpdd.1554","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:50:40Z","timestamp":1748479840000},"page":"700-709","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Microtracer\u2010Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [<sup>14<\/sup>C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study"],"prefix":"10.1002","volume":"14","author":[{"given":"Jayaprakasam","family":"Bolleddula","sequence":"first","affiliation":[{"name":"EMD Serono  Billerica MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Scheible","sequence":"additional","affiliation":[{"name":"The Healthcare Business of Merck KGaA  Darmstadt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Huber","sequence":"additional","affiliation":[{"name":"The Healthcare Business of Merck KGaA  Darmstadt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Seithel\u2010Keuth","sequence":"additional","affiliation":[{"name":"The Healthcare Business of Merck KGaA  Darmstadt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanno","family":"Schieferstein","sequence":"additional","affiliation":[{"name":"The Healthcare Business of Merck KGaA  Darmstadt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepthi S.","family":"Vagge","sequence":"additional","affiliation":[{"name":"Merck Specialities Pvt. Ltd. an affiliate of Merck KGaA, Darmstadt, Germany  Bangalore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadra","family":"Mammasse","sequence":"additional","affiliation":[{"name":"Cytel  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Jaks","sequence":"additional","affiliation":[{"name":"The Healthcare Business of Merck KGaA  Darmstadt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Ferrer","sequence":"additional","affiliation":[{"name":"The Healthcare Business of Merck KGaA  Darmstadt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo","family":"Moulin","sequence":"additional","affiliation":[{"name":"The Healthcare Business of Merck KGaA  Darmstadt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Dong","sequence":"additional","affiliation":[{"name":"EMD Serono  Billerica MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Venkatakrishnan","sequence":"additional","affiliation":[{"name":"EMD Serono  Billerica MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"Papai","sequence":"additional","affiliation":[{"name":"Medical Centre, Hungarian Defence Forces  Budapest Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645010-00003"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/03602530600952172"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12540"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1085"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13403"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6915"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02404"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0058"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4025"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2016.1181081"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac5015035"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.56"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/js970486q"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04184-z"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.079848"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/tx0101189"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000354805"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.048892"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.059345"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.055558"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094724"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.2c00188"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.10.1240"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000220"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.658"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.02.014"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T07:14:12Z","timestamp":1756797252000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/cpdd.1554"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1554","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"type":"print","value":"2160-763X"},{"type":"electronic","value":"2160-7648"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"2025-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}